Eli Lilly and Company (LLY) Halts Experimental Study of Muscle-Sparing Obesity Drug

Core Insights - Eli Lilly and Company has halted an experimental study of Bimagrumab, a drug aimed at preventing muscle loss in obesity patients, due to undisclosed strategic business reasons [1][2][3] - The trial was closed on June 10, less than a month after initiation, while a similar study in non-diabetic obese patients remains active [3] - Eli Lilly's Zepbound, which contains Tirzepatide, is part of the company's obesity treatment portfolio [2][3] - In 2023, Eli Lilly acquired Versanis for nearly $2 billion, gaining access to Bimagrumab, which targets fat cells without causing lean mass loss [4] Company Developments - The company routinely evaluates its clinical development programs to optimize product potential [3] - Several drugmakers are developing therapies in combination with Eli Lilly's Zepbound or Novo Nordisk's Wegovy [3] Market Position - Eli Lilly is recognized as one of the 10 best money-making stocks to invest in [1]